Core Viewpoint - The company has entered into exclusive distribution agreements and investment agreements with Hengtai Optical and Hengtai Vision, which will significantly impact its market position in the high-end contact lens sector in China [1][2]. Group 1: Exclusive Distribution Agreements - The company’s wholly-owned subsidiary, Haohai Biotechnology Holdings, signed an exclusive distribution agreement with Hengtai Optical and Hengtai Vision for the high-end orthokeratology contact lens product "myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also includes the exclusive distribution rights for Hengtai Vision's optical lenses for children's myopia management, named "Beishide," in mainland China [1]. Group 2: Investment Agreement - The company’s subsidiary, Haohai Pharmaceutical Technology Development, has signed an investment agreement to acquire a 55% stake in Hengtai Vision for RMB 25 million, making Hengtai Vision a subsidiary and consolidating it into the company's financial statements [1]. Group 3: Termination of Existing Cooperation - Due to Carl Zeiss Vision International's intention to acquire 100% of Hengtai Optical, the existing cooperation between Haohai Holdings and Hengtai Optical will be terminated, with a compensation payment of RMB 80 million to Haohai Holdings [2]. - Following the termination, Hengtai Vision will transfer 45% of its shares from its minority shareholder to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development [2].
昊海生物科技(06826)与亨泰光学终止OK镜独家合作 获8000万元补偿并全资控股亨泰视觉